CervoMed Inc CRVO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CRVO is a good fit for your portfolio.
News
-
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
-
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
-
CervoMed to Participate in Upcoming Investor Conferences
-
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
-
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024
-
CervoMed to Participate in the BIO CEO and Investor Conference
-
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies
Trading Information
- Previous Close Price
- $23.90
- Day Range
- $23.35–24.82
- 52-Week Range
- $4.14–26.38
- Bid/Ask
- $10.00 / $24.76
- Market Cap
- $203.54 Mil
- Volume/Avg
- 13,574 / 32,701
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.cervomed.com
Valuation
|
Metric
|
CRVO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 18.38 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CRVO
Financial Strength
|
Metric
|
CRVO
|
|---|---|
Quick Ratio | 3.35 |
Current Ratio | 3.84 |
Interest Coverage | — |
Quick Ratio
CRVO
Profitability
|
Metric
|
CRVO
|
|---|---|
Return on Assets (Normalized) | −59.64% |
Return on Equity (Normalized) | −253.57% |
Return on Invested Capital (Normalized) | −139.31% |
Return on Assets
CRVO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hgrzbmys | Lmn | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wffvwsqjv | Gwwvzs | $109.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wfbcnpk | Zmtlsyj | $105.3 Bil | |
MRNA
| Moderna Inc | Szsvdgqt | Plbqr | $47.0 Bil | |
ARGX
| argenx SE ADR | Djvjcmcd | Rlq | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Dbqdxxfv | Mftn | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fkmjbkztb | Tkjxfw | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mkpljknxd | Bsngsg | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jtwmzsmg | Wkqts | $12.7 Bil | |
INCY
| Incyte Corp | Zcmhqykhf | Rzcdzqn | $12.0 Bil |